News >

Blood Test May Predict Palbociclib Response Earlier in Breast Cancer

Jason Harris
Published: Friday, Mar 02, 2018

Nicholas Turner, MD, PhD
Nicholas Turner, MD, PhD
A blood test that detects early changes in circulating tumor DNA (ctDNA) may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to the CDK4/6 inhibitor palbociclib (Ibrance), according to findings published in Nature Communications.

In the United States, palbociclib is approved by the FDA for the treatment of patients with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, or fulvestrant in women with disease progression following endocrine therapy.
O’Leary B, Hrebien S, Morden JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer [published online March 1, 2018]. Nat Commun. doi:10.1038/s41467-018-03215-x.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication